Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 23, 1993 - Issue 7
11
Views
4
CrossRef citations to date
0
Altmetric
Original Article

Metabolic fate of a new dihydropyridine calcium antagonist, CD-349, in rat and dog

, , , &
Pages 747-759 | Received 21 Dec 1992, Accepted 06 May 1993, Published online: 23 Apr 2010
 

Abstract

1. The metabolic fate of 14C-CD-349, a new calcium antagonist, was studied in rat and dog.

2. After oral administration of 14C-labelled drug in both species, the plasma levels of radioactivity reached maxima at 1–2 h and declined with elimination half-lives of 6–7 h. In both species, 71–85% of radioactivity was excreted in faeces and 17–27% in urine in 120h. Biliary excretion in rat after oral doses amounted to 33%.

3. The low ratio of unchanged drug to total radioactivity in plasma suggested that CD-349 underwent rapid metabolism in both species.

4. Twenty-two metabolites were isolated and identified from dog urine and an incubation mixture with 9000 g rat liver supernatant. Principal routes of biotransformation of CD-349 were similar in both species, and involved: (1) oxidation of the dihydropyridine ring to the corresponding pyridine ring; (2) denitration of the nitrate ester; (3) hydrolysis of the carboxy ester to the carboxylic acid; and/or (4) oxidation of the side chain, although quantitative interspecies differences were observed.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.